Us Alzheimers Disease Diagnostics Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The Alzheimer's disease diagnostics market covers clinical tools used to detect, stage, and monitor Alzheimer's disease and related dementias, including neuroimaging equipment, biomarker-based laboratory assays, and digital cognitive testing platforms. The U.S. market was valued at approximately $3.53 billion in 2024 and is forecast to expand at a 10.6% compound annual growth rate through 2030, while the broader North American region, which dominates global share, is expected to reach roughly $5.2 billion by 2026 at an 8.12% growth rate. Imaging techniques currently represent the largest revenue segment, supported by well-established clinical pathways for PET and MRI-based amyloid and tau imaging.

• •U.S. market valued at ~$3.53 billion in 2024; growing at ~10.6% CAGR through 2030
• •North America regional market at ~$3.97 billion in 2024, projected to reach ~$5.2 billion by 2026
• •Imaging techniques are the largest single segment by revenue across the region

A rapidly aging U.S. population is expanding the addressable patient base, as Alzheimer's disease prevalence rises sharply after age 65. Regulatory and reimbursement shifts, including expanded Medicare coverage for PET amyloid imaging and emerging blood-based biomarker tests, are improving patient access and accelerating clinical adoption. Concurrently, the development pipeline for disease-modifying Alzheimer's therapies has created urgent demand for diagnostic tools capable of identifying patients at earlier disease stages, when intervention is most effective.

• •Rising prevalence of Alzheimer's in the 65+ age cohort expanding the addressable market
• •Expanded Medicare reimbursement for amyloid PET imaging and emerging biomarker tests
• •Disease-modifying therapy pipeline driving demand for early-stage diagnostic capabilities

The market is typically segmented by product type, neuroimaging, clinical laboratory biomarker testing, and digital cognitive assessment, with neuroimaging commanding the largest share. Geographically, North America accounts for the dominant share of global Alzheimer's diagnostics revenue, driven by advanced healthcare infrastructure, higher diagnostic awareness, and favorable reimbursement frameworks, while emerging markets in Asia-Pacific are growing at an accelerating pace. The U.S. alone represents the single largest country-level market globally, supported by a high concentration of research hospitals, diagnostic laboratories, and specialized imaging centers.

• •Neuroimaging is the leading segment; lab-based biomarker and digital assessments are the fastest-growing subsegments
• •North America holds the largest regional share globally, with the U.S. as the dominant country market
• •Asia-Pacific is emerging as the fastest-growing regional market outside North America

Who are the notable companies in the industry?

The competitive structure is moderately consolidated, with a tier of large, diversified healthcare and life sciences conglomerates that hold integrated diagnostic and imaging portfolios alongside a layer of more focused specialty diagnostic firms concentrated on neuro-specific biomarker and digital cognitive testing platforms. Capacity and R&D investment are heavily concentrated in the United States and Western Europe, where regulatory pathways for novel diagnostic modalities are most established. Key technology and process routes include neuroimaging systems deployed through hospital and imaging center networks, immunoassay and mass-spectrometry platforms for CSF and emerging blood-based biomarker testing, and software-driven digital cognitive assessment tools delivered through clinical or direct-to-consumer channels.

• •Moderately consolidated market with large integrated healthcare conglomerates alongside specialty diagnostic firms
• •Technology routes: neuroimaging systems, lab-based biomarker immunoassays/mass spectrometry, and digital cognitive assessment software
• •Capacity and R&D concentrated in the U.S. and Western Europe, where regulatory pathways are most mature

What are the recent trends and outlook?

The market is trending toward earlier and less invasive diagnostic protocols, with plasma-based biomarker assays gaining clinical acceptance as alternatives to CSF lumbar puncture procedures. Integration of artificial intelligence into imaging analysis and digital cognitive assessment tools is improving diagnostic speed, accuracy, and accessibility at the point of care. Over the forecast horizon, continued clinical validation of multi-modal diagnostic algorithms and growing emphasis on blood-based tau and phosphorylated-tau assays are expected to further accelerate market expansion and broaden access beyond specialized memory care centers.

• •Blood-based biomarker assays gaining clinical traction as less invasive alternatives to CSF testing
• •AI-assisted imaging analysis and digital cognitive tools expanding point-of-care diagnostic capability
• •Multi-modal diagnostic approaches combining imaging and biomarker data becoming the emerging clinical standard